Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,otherAssets,cash,totalCurrentLiabilities,propertyPlantEquipment,totalCurrentAssets,netReceivables,longTermDebt,inventory,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,changeToNetincome,capitalExpenditures,netBorrowings,otherCashflowsFromFinancingActivities,repurchaseOfStock,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketChangePercent,regularMarketDayRange,ask,bid,regularMarketPreviousClose,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,currency,marketState,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,market,priceHint,exchangeDataDelayedBy,twoHundredDayAverageChangePercent,shortName,exchange,epsCurrentYear,priceEpsCurrentYear,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry,address2
t0,HRMY,-49885000.0,56901000,4679000,,7386000,,7386000,30053000,49265000,14533000,14533000,,-7127000,,,,0,59674000,45141000,10409000,-7147000,,7386000,7386000,157764000.0,588687000.0,229373000.0,107879000.0,262000.0,337252000.0,1000.0,1466000.0,-480809000.0,1023000.0,902000.0,141169000.0,33437000.0,842000.0,177744000.0,23615000.0,194913000.0,4405000.0,4391000.0,1835000.0,-100004000.0,12000.0,-3264000.0,12000.0,-87462000.0,12530000.0,4679000.0,-582000.0,-1439000.0,3251000.0,-4000.0,,,,144307000.0,en-US,US,EQUITY,True,Delayed Quote,1.1212779,32.9 - 34.69,0.0,0.0,33.89,14,8,finmb_679038073,NasdaqGM,"Harmony Biosciences Holdings, Inc.",USD,273800,237428,9.18,0.36588284,25.09 - 52.74,-18.470001,-0.35020858,25.09,52.74,1620720000,1620720000,1620720000,USD,PRE,34.27,1630526403,0.38000107,33.9,34.69,32.9,207356,us_market,2,0,0.11850172,"Harmony Biosciences Holdings, I",NGM,1.02,33.59804,29.968857,4.3011436,0.14352044,30.639202,3.6307983,1949997312,15,America/New_York,EDT,-14400000,False,False,,,,52.74,25.09,29.97,30.64,273.8k,237.43k,56.9M,,22.31M,18.85%,74.79%,637.97k,2.49,3.56%,1.12%,492.5k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",4.54%,20.61%,10.27%,29.38%,199.58M,5.24,200.80%,132M,54.16M,-7.4M,,,141.17M,2.48,194.91M,180.68,5.32,,36.25M,-71.28M,Value,19462,Healthcare,150,9,7,"Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United States. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.",Plymouth Meeting,484 539 9800,PA,8,1609372800,1622505600,10,United States,http://www.harmonybiosciences.com,86400,10,630 West Germantown Pike,Biotechnology,Suite 215
t-1,HRMY,-65163000.0,56901000,7619000,,-208000,,-208000,30993000,46370000,7758000,7758000,,-7966000,,,,0,56288000,48530000,9918000,-7966000,,-208000,-208000,162343000.0,585374000.0,329894000.0,97180000.0,100314000.0,427074000.0,1000.0,1302000.0,-488195000.0,1105000.0,902000.0,228631000.0,134539000.0,938000.0,262891000.0,22176000.0,194250000.0,3823000.0,2556000.0,-6791000.0,-2000000.0,-1156000.0,13710000.0,16000.0,6891000.0,10047000.0,4383000.0,-1512000.0,-5851000.0,4924000.0,-4000.0,102538000.0,-103710000.0,,128352000.0,en-US,US,EQUITY,True,Delayed Quote,1.1212779,32.9 - 34.69,0.0,0.0,33.89,14,8,finmb_679038073,NasdaqGM,"Harmony Biosciences Holdings, Inc.",USD,273800,237428,9.18,0.36588284,25.09 - 52.74,-18.470001,-0.35020858,25.09,52.74,1620720000,1620720000,1620720000,USD,PRE,34.27,1630526403,0.38000107,33.9,34.69,32.9,207356,us_market,2,0,0.11850172,"Harmony Biosciences Holdings, I",NGM,1.02,33.59804,29.968857,4.3011436,0.14352044,30.639202,3.6307983,1949997312,15,America/New_York,EDT,-14400000,False,False,,,,52.74,25.09,29.97,30.64,273.8k,237.43k,56.9M,,22.31M,18.85%,74.79%,637.97k,2.49,3.56%,1.12%,492.5k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",4.54%,20.61%,10.27%,29.38%,199.58M,5.24,200.80%,132M,54.16M,-7.4M,,,141.17M,2.48,194.91M,180.68,5.32,,36.25M,-71.28M,Value,19462,Healthcare,150,9,7,"Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United States. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.",Plymouth Meeting,484 539 9800,PA,8,1609372800,1622505600,10,United States,http://www.harmonybiosciences.com,86400,10,630 West Germantown Pike,Biotechnology,Suite 215
t-2,HRMY,27924000.0,56901000,4230000,,1909000,,1909000,23109000,37719000,10380000,10380000,,-6946000,,,,0,45609000,35229000,7890000,-8471000,,1909000,-4104000,66625000.0,582535000.0,225524000.0,94549000.0,,320073000.0,1000.0,5625000.0,-487987000.0,876000.0,2168000.0,221740000.0,31790000.0,1038000.0,250242000.0,16326000.0,192858000.0,2311000.0,9347000.0,7274000.0,-2000000.0,136622000.0,-4194000.0,147660000.0,145460000.0,8838000.0,1967000.0,-228000.0,-1087000.0,2855000.0,-4000.0,102538000.0,-11021000.0,-17000.0,218452000.0,en-US,US,EQUITY,True,Delayed Quote,1.1212779,32.9 - 34.69,0.0,0.0,33.89,14,8,finmb_679038073,NasdaqGM,"Harmony Biosciences Holdings, Inc.",USD,273800,237428,9.18,0.36588284,25.09 - 52.74,-18.470001,-0.35020858,25.09,52.74,1620720000,1620720000,1620720000,USD,PRE,34.27,1630526403,0.38000107,33.9,34.69,32.9,207356,us_market,2,0,0.11850172,"Harmony Biosciences Holdings, I",NGM,1.02,33.59804,29.968857,4.3011436,0.14352044,30.639202,3.6307983,1949997312,15,America/New_York,EDT,-14400000,False,False,,,,52.74,25.09,29.97,30.64,273.8k,237.43k,56.9M,,22.31M,18.85%,74.79%,637.97k,2.49,3.56%,1.12%,492.5k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",4.54%,20.61%,10.27%,29.38%,199.58M,5.24,200.80%,132M,54.16M,-7.4M,,,141.17M,2.48,194.91M,180.68,5.32,,36.25M,-71.28M,Value,19462,Healthcare,150,9,7,"Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United States. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.",Plymouth Meeting,484 539 9800,PA,8,1609372800,1622505600,10,United States,http://www.harmonybiosciences.com,86400,10,630 West Germantown Pike,Biotechnology,Suite 215
t-3,HRMY,-551854000.0,56901000,4169000,,-27000,,-27000,18925000,31549000,8455000,8455000,,-6936000,,,,0,38005000,29550000,6456000,-8482000,,-27000,-10473000,68492000.0,,214227000.0,-483362000.0,,168819000.0,1000.0,16000.0,-483363000.0,648000.0,902000.0,76280000.0,21061000.0,1138000.0,98287000.0,15239000.0,192518000.0,2083000.0,2073000.0,-2778000.0,-2000.0,-67000.0,8537000.0,100000.0,4763000.0,4832000.0,2004000.0,-212000.0,-3931000.0,899000.0,-2000.0,102538000.0,-11021000.0,-167000.0,77226000.0,en-US,US,EQUITY,True,Delayed Quote,1.1212779,32.9 - 34.69,0.0,0.0,33.89,14,8,finmb_679038073,NasdaqGM,"Harmony Biosciences Holdings, Inc.",USD,273800,237428,9.18,0.36588284,25.09 - 52.74,-18.470001,-0.35020858,25.09,52.74,1620720000,1620720000,1620720000,USD,PRE,34.27,1630526403,0.38000107,33.9,34.69,32.9,207356,us_market,2,0,0.11850172,"Harmony Biosciences Holdings, I",NGM,1.02,33.59804,29.968857,4.3011436,0.14352044,30.639202,3.6307983,1949997312,15,America/New_York,EDT,-14400000,False,False,,,,52.74,25.09,29.97,30.64,273.8k,237.43k,56.9M,,22.31M,18.85%,74.79%,637.97k,2.49,3.56%,1.12%,492.5k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",4.54%,20.61%,10.27%,29.38%,199.58M,5.24,200.80%,132M,54.16M,-7.4M,,,141.17M,2.48,194.91M,180.68,5.32,,36.25M,-71.28M,Value,19462,Healthcare,150,9,7,"Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United States. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.",Plymouth Meeting,484 539 9800,PA,8,1609372800,1622505600,10,United States,http://www.harmonybiosciences.com,86400,10,630 West Germantown Pike,Biotechnology,Suite 215
